ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) - GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - ARCUTIS BIOTHERAPEUTICS INC

Explicit Guidance:

• Revenue: Projected to reach peak sales of $2.3 to $3.5 billion; currently generating over $500 million annually with momentum toward $1 billion.
• Cash Flow/Profitability: Maintained cash flow positivity since late 2025 and expected to continue throughout 2026 and 2027; profitable in 3 of the last 4 quarters (net income positive); Q4 2026 expected to maintain steady-state gross net without significant price changes but with volume growth.
• Operating Expenses: Intends to stay cash flow positive during 2027; notes potential for occasional quarterly cash mismatches (e.g., March due to bonuses and non-cash expenses) but expects steady annual accumulation.

Business-Segment Outlook:

• Zareve (Qd 305 / crisaborole):
  • Indications: Pediatric approval expected end of February 2027; Phase III study for moderate-to-severe Atopic Dermatitis (AD) ongoing; AD "infinite" indication expected in March; Phase II trials for Vitiligo and Hidradenitis Suppurativa (HS) in progress.
  • Market Penetration: Current branded non-steroidal market share at ~10% (3.5% of total market); targeting 15–20% penetration to achieve peak sales.
  • Usage Metrics: Patients currently consume 2–3 units per year across indications (Psoriasis, AD, Seborrheic Dermatitis); foam formulation noted to have higher consumption due to ease of application.
• Commercial Expansion:
  • Sales Force: Dermatology team expansion in 2026 driving growth continuing into 2027; Primary Care and Pediatric teams launched 3 months prior to Q4 2026, expected to become major growth drivers in 2027.
  • Marketing: Partnership with Simone Biles (spokesperson) to raise awareness for Seborrheic Dermatitis and Eczema (AD).
  • Formulation Strategy: Foam formulation expected to be a key differentiator in HS due to application in sensitive areas (groin, axillae); dual cream/foam portfolio enhancing payer leverage and physician habit formation.

Market and Competitive Outlook:

• Market Shift: Accelerating structural shift away from topical steroids due to long-term safety concerns in chronic conditions; AAD guidelines now prefer non-steroidals over topical steroids for pediatric use.
• Competitive Landscape: New non-steroidals (including Arcutis) driving a conversation in dermatology to move away from steroids; positioning Zareve as "best-in-class" with faster efficacy, deeper response, and tolerability advantages over JAK inhibitors and other current therapies.
• Market Size: Dermatology historically writes 16x more topical steroids than branded non-steroidals; minimal share shift required to unlock multi-billion dollar opportunity.
• Payer Dynamics: Multiple indications expected to increase volume and strengthen rebate leverage against new entrants; no significant complication expected for payers due to cream/foam portfolio.

Macro / Industry Outlook:

• Regulatory Environment: Growing momentum among physician and patient groups to petition the FDA for updated steroid labels regarding safety; AAD's new guidelines signal regulatory/clinical acceptance of non-steroidal shift.
• Healthcare Spending: Patients spending more on healthcare, contributing to early achievement of steady-state gross net despite lack of price changes in Q3/Q4 2026.
• Asset Valuation: Sale of Zareve royalties to Royalty Pharma (10-year window from 2022 launch) validates $2.3–$3.5 billion peak sales potential and implies the transaction value is in line with peak sales projections.

Strategic Initiatives:

• M&A/Development: Acquisition of ARQ234 (PDE4 inhibitor) for AD and potential autoimmune disorders; Phase I multiple ascending dose enrollment underway, with proof-of-concept (POC) study to follow for AD; potential expansion to other indications if AD data succeeds.
• Pipeline Stacking: Building pipeline for 2023–2024 and beyond using leverage from 2026 cash flow; focus on biologically validated targets in large markets with high unmet need (e.g., Vitiligo, HS).
• Intellectual Property: Patent protection secured for cream until 2037 and foam until 2042 (including 4 unique foam-specific patents); actively seeking opportunities to expand IP estate.
• Capital Allocation: Prioritizes reinvestment in sales force expansion, marketing, and pipeline building; BD deals viewed as "nice-to-have" rather than "must-have" to avoid destroying shareholder value.

Risks and Headwinds to Outlook:

• Clinical Execution: Future growth in Vitiligo, HS, and AD depends on successful completion of Phase II and III trials; failure in these studies would limit expansion beyond current indications.
• Cash Flow Variability: Potential for occasional quarterly cash mismatches or non-cash expenses (e.g., March bonuses) despite positive annual trends.
• Clinical Success Dependency: Peak sales projections ($2.3–$3.5B) are contingent on success in indicated expansion studies (Vitiligo, HS, moderate-to-severe AD).
• Market Adoption: While momentum is strong, the transition from steroids to non-steroidals relies on sustained physician education and acceptance of new safety profiles.

Management Tone on the Future:

• Confidence: Describes 2027 outlook as "bullish" and "confident"; characterized by "very strong performance" and "outstanding team" execution.
• Validation: Management views the $2.3–$3.5B peak sales narrative as underappreciated by the street, noting they have already disproven the "topicals can't be big" narrative.
• Growth Trajectory: Expresses expectation that the 10% current branded non-steroidal market share represents only the "tip of the iceberg," with 90% of the opportunity remaining.
• Team Strength: Highlights the addition of CCO Rob Lesicki and the strength of the commercial team as a primary driver of continued outperformance.

Miscellaneous:

• Q4 2026 Seasonality: Anticipated to follow standard seasonality with the strongest quarter of the year; no expected price changes, focusing on volume growth.
• Pricing Strategy: Achieved steady-state gross net early in 2026; no price changes expected in Q4 2026 or beyond.
• Post-Inflammatory Hypopigmentation (PIH): Noted rapid resolution of PIH in AD and Seborrheic Dermatitis trials within 8 weeks, supporting efficacy in pigmentary disorders like Vitiligo.